The pharmaceutical company announced that the US drug regulator has concluded its inspection at the new injectable facility in Andhra Pradesh, with three observations.
The new injectable facility of Eugia Steriles (a 100% subsidiary of Eugia Pharma Specialities and a stepdown subsidiary of the company), situated at Parawada Mandal, Anakapalli district, Andhra Pradesh, has recently started the commercial operations.
The United States Food and Drug Administration (USFDA) inspected the facility from 28 March 2024 to 5 April 2024.
The inspection closed with three observations. The observations are procedural in nature and will be responded to within the stipulated time, the company stated in the press release.
On 6 April 2024, the company informed that an accident occurred near Vacuum Tray Dryer (VTD) area at Unit 6 of Apitoria Pharma (wholly owned subsidiary of the company), situated at Parawada, Anakapalli district, Andhra Pradesh. The firm said that there was one casualty due to the accident.
Further, the company added the unit continues its normal operations.
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.
The drug maker reported 90.58% jump in consolidated net profit to Rs 936.29 crore on 13.82% rise in revenue from operations to Rs 7,271.23 crore in Q3 FY24 over Q3 FY23.
The scrip shed 0.19% to end at Rs 1,121 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
